Pooled analysis of routine safety parameters observed in healthy participants at baseline and following placebo administration in early phase clinical studies by Kelly E. Duncan, Runcheng Li, Lata Maganti, Amit Kumar, S. Aubrey Stoch, Geoffrey A. Walford

Connect to this object online.

Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans by Jesse C. Nussbaum, Azher Hussain, Bennett Ma, K. Chris Min, Qing Chen, Charles Tomek, Marian Iwamoto, S. Aubrey Stoch

Connect to this object online.

Assessment of pharmacokinetics, safety, and tolerability following twice‐daily administration of molnupiravir for 10 days in healthy participants by Marian Iwamoto, Kelly E. Duncan, Prachi K. Wickremasingha, Tian Zhao, Maria V. Liberti, Lieselotte Lemoine, Tatjana Decaesteker, Sylvie Rottey, Brian M. Maas, Gillian Gillespie, S. Aubrey Stoch

Connect to this object online.

Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV by Randolph P. Matthews, Wendy Ankrom, Evan Friedman, Deanne Jackson Rudd, Yang Liu, Robin Mogg, Deborah Panebianco, Inge De Lepeleire, Magdalena Petkova, Jay A. Grobler, Selwyn Aubrey Stoch, Marian Iwamoto

Connect to this object online.

O6 Single doses as low as 0.5 mg of the novel NRTTI MK-8591 suppress HIV for at least 7 days by Inge De Lepeleire, Randolph P. Matthews, Dirk Schürmann, Deanne J. Rudd, Vanessa Levine, Sabrina Fox-Bosetti, Sandra Zhang, Martine Robberechts, Andreas Hüser, DariaJ Hazuda, JayA Grobler, Aubrey Stoch, Marian Iwamoto

Connect to this object online.